NCT05334927

China HeadAche DIsorders RegiStry

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 10,000 (estimated)
• Sponsor: Beijing Tiantan Hospital · Academic / Other
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

It is planned to include 10000 patients. In the China HeadAche DIsorders RegiStry CHAIRS）, patients aged over 12 years with primary headache and medication-overuse headache(MOH) were collected. The biomarkers, imaging features, cognition, genetic characteristics, ocial and demographic data, medical data, therapeutics used, and outcome of headache-related diseases were studied, and long-term follow-up was planned.

Conditions

• Headache Disorders, Primary
• Migraine
• New Daily Persistent Headache
• Medication Overuse Headache
• Tension-Type Headache
• Trigeminal Autonomic Cephalalgia

Interventions

Type	Name	Description
BEHAVIORAL	Medicine Overuse Headache/New Daily Persistent Headache	At the end of the 24th month visit, the patient is free to choose whether to conduct a face-to-face visit once a year until death.
BEHAVIORAL	Episodic Migraine and Chronic Migraine	long-term follow-up
BEHAVIORAL	Patients with other types of primary headache	No collection Brain imaging、Cognitive function test、Biological sample
DRUG	Yangxue Qingnao Granules (Pills)	Participants who, in routine clinical practice, were prescribed Yangxue Qingnao Granules/Pills for acute headache relief and/or preventive management were enrolled. Treatment initiation, dosing, frequency, and duration were determined by the treating physician and the patient and were not assigned by the study protocol. During the 12-week observation period, participants were followed and outcomes were recorded, including relief of up to four headache episodes (for those using the medication for acute treatment) and longitudinal symptom measures at weeks 4, 8, and 12 (for those receiving preventive management).
BIOLOGICAL	Erenumab	Participants who received eptinezumab for migraine prophylaxis in routine clinical practice were included. Treatment decisions (including whether to initiate eptinezumab, the selected dose \[e.g., 100 mg or 300 mg\], infusion interval, and duration) were made by the treating physician in consultation with the patient, and were not assigned by the study protocol. Patients were followed prospectively/retrospectively according to routine clinic visits, with outcome assessments captured at approximately 4-week intervals during the 12-week observation window (and additional follow-up when available).
BIOLOGICAL	Eptinezumab	Participants who received eptinezumab for migraine prophylaxis in routine clinical practice were included. Treatment decisions (including whether to initiate eptinezumab, the selected dose \[e.g., 100 mg or 300 mg\], infusion interval, and duration) were made by the treating physician in consultation with the patient, and were not assigned by the study protocol. Patients were followed prospectively/retrospectively according to routine clinic visits, with outcome assessments captured at approximately 4-week intervals during the 12-week observation window (and additional follow-up when available).

Timeline

• Start date: 2022-08-29
• Primary completion: 2031-12-31
• Completion: 2032-12-31
• First posted: 2022-04-19
• Last updated: 2026-01-15

Locations

20 sites across 1 country: China